|1.||Ueoka, Ryuichi: 26 articles (07/2015 - 04/2002)|
|2.||Matsumoto, Yoko: 20 articles (07/2015 - 04/2002)|
|3.||Ichihara, Hideaki: 11 articles (07/2015 - 01/2003)|
|4.||Komizu, Yuji: 9 articles (06/2013 - 12/2006)|
|5.||Goto, Koichi: 9 articles (06/2013 - 04/2002)|
|6.||Hino, Motoki: 4 articles (07/2015 - 01/2011)|
|7.||Matsushita, Taku: 3 articles (07/2010 - 06/2005)|
|8.||Iwamoto, Yasunori: 3 articles (06/2005 - 11/2002)|
|9.||Villena, F: 2 articles (11/2015 - 05/2009)|
|10.||Suwalsky, M: 2 articles (11/2015 - 05/2009)|
10/01/2015 - "These results suggest that the DSPC liposomal formulation is a promising formulation for MDR tumor therapy over DMPC and DPPC formulations and free drug."
10/01/2015 - "The DSPC formulation displayed the highest drug accumulation in the tumor with 2-fold, 3-fold and 100-fold increases compared to DPPC, DMPC and free CDDP respectively. "
11/01/2012 - "GC patients with DMPC had a significantly higher age (p <0.0001) and higher incidence of differentiated cancer(p=0.0045) than those without DMPC. "
05/08/2009 - "To evaluate the in vivo capability of 1-MTX to radiosensitize tumors, we developed temperature-sensitive liposomal 1-MTX using DPPC:DMPC:DSPC (4:1:1 molar ratio) with intention of overcoming lethal toxicity of 1-MTX and controlling drug-release. "
11/01/2012 - "An aging population and advances in diagnostic technology have led to an increase in the incidence of double or multiple primary cancers(DMPC) in patients with gastric cancer(GC). "
|2.||Breast Neoplasms (Breast Cancer)
08/01/2012 - "DMpC therapy appears to have few side effects and might be an effective treatment option for recurrent breast cancer patients with a poor general health condition."
05/01/2005 - "DMpC therapy could thus be one the most useful treatments for advanced breast cancer."
03/01/2002 - "[Successful treatment of advanced recurent breast cancer using DMpC therapy as maintenance therapy]."
12/01/2008 - "Oral anti-cancer treatments such as DMpC appear to have few side effects and might be an effective treatment option for recurrent breast cancer patients with triple negative disease."
12/01/2008 - "[Doxifluridine, medroxyprogesterone acetate and cyclophosphamide (DMpC) combination therapy is effective against recurrent triple negative breast cancer--a case report]."
|3.||Neoplasm Metastasis (Metastasis)
01/01/2011 - "Therapeutic effects of DMPC/DHA without any drugs on the hepatic metastasis were revealed on the basis of histological and biochemical analyses for the first time in vivo."
01/01/2011 - "Furthermore, prolonged survival was obtained in the hepatic metastasis mouse models after the treatment with DMPC/DHA. "
01/01/2011 - "The histological analysis indicated the induction of apoptosis was observed in the liver section of the hepatic metastasis mouse models treated with DMPC/DHA in vivo. "
01/01/2011 - "Remarkably high therapeutic effects were obtained in the hepatic metastasis mouse models of HCT116 cells after the intravenous injection of DMPC/DHA. "
09/01/2014 - "HL composed of 95 mol% DMPC and 5 mol% C12(EO)25 were prepared by the sonication method and their therapeutic effects in xenograft mouse models of colorectal cancer liver metastases were examined in vivo. "
05/01/2010 - "In addition, treatment of Ad in the PL state showed enhanced green fluorescent protein (GFP) expression when compared with treatment with Ad alone or with DMPC-Ad in hepatoma and brain glioma cells. "
12/04/2000 - "Three-component hybrid liposomes composed of L-alpha-dimyristoylphosphatidylcholine, micellar surfactant (Tween 20), and beta-D-fructofuranosyl-alpha-D-glucopyranoside monododecanoate were found to be highly effective for inhibiting the growth of glioma cells without any drug."
04/01/2002 - "It is noteworthy that high inhibitory effects of the three-component hybrid liposomes composed of DMPC, Tween 20, and LacCn (DMPC:Tween 20:LacCn=65:7:28) on the growth of glioma (U251) and lung adenocarcinoma (RERF-LC-OK) cells were attained in vitro without any drug, although no significant inhibitory effects of any individual component (DMPC, Tween 20, LacCn) or the two-component hybrid liposomes of DMPC and Tween 20 on the growth of tumor cells examined were obtained."
02/01/2010 - "Liposomes formulated with dimyristoyl-sn-glycero-phosphatidylcholine, DMPC, and either one of the cationic gemini surfactants (S,S)-2,3-dimethoxy-1,4-bis(N-hexadecyl-N,N-dimethylammonio)butane bromide, 1a, and (S,R)-2,3-dimethoxy-1,4-bis(N-hexadecyl-N,N-dimethylammonio)butane bromide, 1b, were investigated as vehicles of the photosensitizer m-tetrahydroxyphenylchlorin, m-THPC, to cell models of malignant glioma. "
03/01/2007 - "In this study we investigated the feasibility of mixed liposomes formed by dimyristoyl-sn-glycero-phosphatidylcholine (DMPC) and cationic gemini surfactant (Gemini 1) loaded with the chlorin m-tetrahydroxyphenylchlorin (m-THPC), in photodynamic therapy (PDT) for glioma. "
|2.||Medroxyprogesterone Acetate (Depo-Provera)
|10.||Ethyl Ether (Ether)
|1.||Photochemotherapy (Photodynamic Therapy)
|2.||Heterologous Transplantation (Xenotransplantation)